{"id":3636,"date":"2020-06-10T14:21:17","date_gmt":"2020-06-10T14:21:17","guid":{"rendered":"http:\/\/wordpress.mytomorrows.com\/?p=3636"},"modified":"2024-02-27T13:26:53","modified_gmt":"2024-02-27T13:26:53","slug":"a-brief-history-of-expanded-access-part-2","status":"publish","type":"post","link":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/","title":{"rendered":"A Brief History of Expanded Access (Pt. 2) 2014 – 2020"},"content":{"rendered":"
\n

A look at how Expanded Access is moving into the mainstream and changing the way drugs are developed.<\/p>\n<\/div>\n

\n
\n

2014 \u2014 Colorado State first to adopt the Right to Try Act<\/strong><\/h3>\n

Colorado became the first state to pass a Right to Try law in May of 2014. This law gave terminally ill patients the right to use investigational drugs outside of the purview of the FDA. At the time, these laws were being advanced in several states by patient advocates who were frustrated by the amount of time the federal approval process took to access investigational drugs. Missouri, Louisiana, and many other states followed suit. This controversial piece of legislation would later go on to be passed at the federal level. The law made provision for patients to access investigational drugs as early as after completion of phase 1 of development (i.e. in the absence of efficacy data). Opponents of the Right to Try Act were of the opinion that this was an ill-advised effort that circumvented federal law while also undermining the drug development process. They felt that the law threatened to harm more people than it helped by providing access to medications that have not been proven to be safe and effective.<\/p>\n

In the United Kingdom, the Early Access to Medicines Scheme (EAMS) was introduced. EAMS is intended to treat, diagnose, or prevent seriously debilitating or life-threatening conditions. Doctors are allowed to use the scheme (when no other adequate treatment is available) to access new unlicensed and off-label drugs for eligible U.K. patients who have a high unmet medical need.<\/p>\n

The Ebola Crisis in West Africa began in 2014, leading the World Health Organization and Ebola Taskforce together with several governments to advocate for the use of investigational drugs through Expanded Access Programs to treat Ebola patients.<\/p>\n<\/div>\n<\/div>\n

\n
\n
\"European
European Parliament Building<\/figcaption><\/figure>\n<\/div>\n<\/div>\n
\n
\n

2016 \u2014 From Washington, D.C. to Europe, new policies emerge<\/strong><\/h3>\n

Certain patient advocates had widely claimed that filing paperwork for Expanded Access routinely took over 100 hrs. In response, the FDA removed some of the Expanded Access-related questions from the IND application form and created Form 3926. The agency claimed they streamlined the process and reduced the time needed to complete it to 45 minutes.<\/p>\n

It also updated the final guidance on \u201cCharging for Investigational Drugs under an IND.\u201d This added valuable relevant information to the agency\u2019s \u201cRegulation on Charging for Investigational Drugs under an IND for either Clinical Trials or Expanded Access for treatment use.\u201d<\/p>\n

Further, an important step was taken to simplify the process for physicians seeking access to an investigational product to treat their patients. Only one Institutional Review Board member \u2014the Chair or another appropriate person \u2014 could now approve the treatment. The FDA believes that this improved process expedites the facilitation of access while still protecting patients.<\/p>\n

The 21st Century Cures Act was passed in response to the Right to Try Act. This legislation required drug developers to disclose their Expanded Access Policy on the Clinical Trials database, ClinicalTrials.gov, as well as publish their policy on their website. These requirements were embedded in the Final Rule.<\/p>\n

The European Medicines Agency (EMA) launched the Priority Medicines Scheme (PRIME) in 2016. PRIME is designed to optimize the drug development process to allow patients to benefit as early as possible from novel therapies. These therapies must address an unmet medical need and their path to market authorization is expedited based on early clinical data.<\/p>\n

<\/h2>\n<\/div>\n<\/div>\n
\n
\n
\"Mural
Mural by Do-ho Suh in the FDA\u2019s headquarters<\/figcaption><\/figure>\n<\/div>\n<\/div>\n
\n
\n

2017 \u2014 FDA revises guidance on adverse events and launches \u201cExpanded Access Navigator\u201d<\/strong><\/h3>\n

The FDA released final guidance on Expanded Access for the industry entitled, \u201cExpanded Access to Investigational Drugs for Treatment Use: Questions and Answers.\u201d In this revised guidance, the FDA clarified how adverse event data from Expanded Access would be considered in the drug approval process and clarified which other factors the agency would consider in the review process.<\/p>\n

This came after a U.S. Government Accountability Office (GAO) report highlighting stakeholder issues such as the patient and physician journey. It found that while the FDA had taken steps to improve the Expanded Access Program, it still needed to further clarify how adverse events data were viewed. Drug developers and sponsors often indicate they are fearful of being issued a clinical hold order because of adverse events from Expanded Access Programs.<\/p>\n

The Reagan-Udall Foundation, a non-profit organization created to help the FDA accomplish its mission, launched an online \u201cExpanded Access Navigator\u201d to help patients and physicians understand the processes and programs associated with Expanded Access.<\/p>\n

Around the same time, the European Organization for Rare Diseases (EURORDIS) issued a report called\u00a0 \u201cEarly Access to Medicines in Europe \u2013 Compassionate use to become a reality.\u201d<\/a> It argued for Compassionate Use Programmes for medicines to be made more widely available to those patients in need of urgent help. In addition, EURORDIS recommended that the EU adopt the French ATU system or adopt an EU Regulation which would confer a greater role to the EMA in the organization of Compassionate Use programs.<\/p>\n

Meanwhile the Italian government, under Ministerial Decree, issued new rules on Expanded Access to medicinal products. These stated that Expanded Access may be sought for non-authorized products. It thus allowed Expanded Access requests to be sought for non-authorized products, as well as for medicinal products that are authorized in Italy or abroad and used for an off-label indication. It also made provision for the use of drugs that were authorized abroad but not yet in Italy. Expanded Access may also be requested for advanced therapy medicinal products (ATMPs) such as gene and cell therapies.<\/p>\n

2018 \u2014 FDA\u2019s response to the Federal Right to Try Act<\/strong><\/h3>\n

The Right to Try Act, or the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act, was signed into law on May 30, 2018. This law potentially provides another way for patients who have been diagnosed with a life-threatening disease, have tried all approved treatment options, and are unable to participate in a Clinical Trial, access to certain pre-approval treatments.<\/p>\n

The whole movement was backed by the Goldwater Institute, a libertarian think-tank from Arizona. The passage of the Right to Try Act renewed public interest in how patients might gain access to therapeutic options. This legislation created an alternative pathway to the FDA\u2019s Expanded Access regulations and ostensibly another way for patients to access drugs that are still in development. Many controversies surround its implementation, chief amongst these is that the law allows physicians and drug companies to implement an investigational treatment protocol without, or with limited, external oversight.<\/p>\n

In November of this year, the FDA organized a workshop around Expanded Access and leveraging treatment data, hosted by the Reagan-Udall Foundation. During this public meeting, FDA officials stressed that data collected by sponsors and their Expanded Access programs are useful in supplementing Clinical Trial data and may help inform regulatory decision-making. Panellists advocated for a flexible and case-by-case approach from the agency rather than establishing a new regulation.<\/p>\n

The long-awaited \u201cExpanded Access Program report\u201d compiled by McKinsey & Co was released in 2018. This report highlighted that the multi-stakeholder environment as well as the absence of standard processes and policies, created confusion around Expanded Access. It also found that drug developers reported challenges particularly related to uncertainty about how the FDA uses adverse event data from Expanded Access Programs. Additionally, they reported difficulty in managing divergent requirements and guidance from foreign health authorities.<\/p>\n<\/div>\n<\/div>\n

\n
\n

2019 \u2014 Project Facilitate aims to improve access to investigational cancer drugs<\/strong><\/h3>\n

Project Facilitate was launched by the FDA. The pilot project established a call center as a single point of contact for physicians to submit single-patient Expanded Access requests for oncology patients. In addition, then-FDA commissioner Scott Gottlieb issued a statement on Post-Trial Access (PTA)<\/a>\u00a0encouraging developers to use the Expanded Access mechanism to allow promising drugs to continue to be provided to patients after the completion of a Clinical Trial.<\/p>\n

Another GAO report was released. It highlighted that drug developers and other stakeholders were largely supportive of steps taken by the FDA to facilitate access to Investigational New Drugs through Clinical Trials, Expanded Access, or Right to Try requests. The report looked closely at actions the FDA had taken to broaden Clinical Trial eligibility criteria, improve access to Investigational Drugs outside of Clinical Trials as well communicate with patients.<\/p>\n

2020 and beyond \u2014 Expanded Access increasingly becomes a public health priority<\/strong><\/h3>\n

Public health emergencies such as the Ebola crisis and the ongoing COVID-19 pandemic, have prompted governments as well as global health organizations, such as WHO, to increasingly recognize the importance of Expanded Access as a mechanism for access. The urgency and severity of the COVID-19 pandemic have bolstered the acceptability and utility of Expanded Access globally. In a similar fashion to the AIDS epidemic in the 1980s, global health organisations as well as regulatory authorities are now having to balance concerns such as scientific process and patient safety against an urgent duty of care.<\/p>\n

Expanded Access continues to evolve in response to a wide range of signals and triggers from a variety of stakeholders across disparate disease areas. While regulatory authorities in different parts of the world may have varying approaches to developing and implementing Expanded Access mechanisms, it is clear that processes, programs, and initiatives that credibly engage all stakeholders are more likely to have the most benefit for patients.<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Regulatory agencies, including the FDA, have come under pressure from patient advocates to facilitate earlier access to investigational new drugs.<\/p>\n","protected":false},"author":12,"featured_media":4839,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[49,50],"tags":[113,135],"class_list":["post-3636","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare-professionals","category-biopharma","tag-expanded-access-programs","tag-compassionate-use"],"acf":[],"yoast_head":"\nA Brief History of Expanded Access (Pt. 2) 2014 - 2020 - myTomorrows<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"ar_AR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A Brief History of Expanded Access (Pt. 2) 2014 - 2020\" \/>\n<meta property=\"og:description\" content=\"Regulatory agencies, including the FDA, have come under pressure from patient advocates to facilitate earlier access to investigational new drugs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/\" \/>\n<meta property=\"og:site_name\" content=\"myTomorrows\" \/>\n<meta property=\"article:published_time\" content=\"2020-06-10T14:21:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-02-27T13:26:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/main-portal.develop-mytomorrows.com\/wp-content\/uploads\/2020\/06\/shutterstock_2292002323.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1400\" \/>\n\t<meta property=\"og:image:height\" content=\"933\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dennis Akkaya\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Akkaya\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 \u062f\u0642\u0627\u0626\u0642\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/\",\"url\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/\",\"name\":\"A Brief History of Expanded Access (Pt. 2) 2014 - 2020 - myTomorrows\",\"isPartOf\":{\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/main-portal.develop-mytomorrows.com\/wp-content\/uploads\/2020\/06\/shutterstock_2292002323.jpg\",\"datePublished\":\"2020-06-10T14:21:17+00:00\",\"dateModified\":\"2024-02-27T13:26:53+00:00\",\"author\":{\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#\/schema\/person\/b7be59ac2b5f8aea751c2b85d116402e\"},\"breadcrumb\":{\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#breadcrumb\"},\"inLanguage\":\"ar\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#primaryimage\",\"url\":\"https:\/\/main-portal.develop-mytomorrows.com\/wp-content\/uploads\/2020\/06\/shutterstock_2292002323.jpg\",\"contentUrl\":\"https:\/\/main-portal.develop-mytomorrows.com\/wp-content\/uploads\/2020\/06\/shutterstock_2292002323.jpg\",\"width\":1400,\"height\":933,\"caption\":\"Strasbourg, France - Apr 23, 2017: Fantastic view of European Parliament headquarters view from the Freedom bridge with reflection in Ill river and all Eu Members flags waving\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A Brief History of Expanded Access (Pt. 2) 2014 – 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#website\",\"url\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/\",\"name\":\"myTomorrows\",\"description\":\"Helping patients discover and access treatments\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ar\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#\/schema\/person\/b7be59ac2b5f8aea751c2b85d116402e\",\"name\":\"Dennis Akkaya\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ar\",\"@id\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/08df14c0e203d864844886d2fccb5743e4e7f8312cea375e51edd4ea0803ed6f?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/08df14c0e203d864844886d2fccb5743e4e7f8312cea375e51edd4ea0803ed6f?s=96&d=blank&r=g\",\"caption\":\"Dennis Akkaya\"},\"description\":\"Based in New York and operating from the US office, Dennis holds an MSc in Finance, has over 20 years of BioPharma industry experience, and is a recognized thought leader in pre-approval access and with specific expertise in clinical trials. Over 8 years at myTomorrows, his role is pivotal in creating biopharma sponsorships. His extensive background, encompassing both BioPharma and finance, well positions him to develop strategic partnerships and drive the discussion within the pre-approval access space.\",\"url\":\"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/author\/dennis-akkaya\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"A Brief History of Expanded Access (Pt. 2) 2014 - 2020 - myTomorrows","robots":{"index":"noindex","follow":"follow"},"og_locale":"ar_AR","og_type":"article","og_title":"A Brief History of Expanded Access (Pt. 2) 2014 - 2020","og_description":"Regulatory agencies, including the FDA, have come under pressure from patient advocates to facilitate earlier access to investigational new drugs.","og_url":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/","og_site_name":"myTomorrows","article_published_time":"2020-06-10T14:21:17+00:00","article_modified_time":"2024-02-27T13:26:53+00:00","og_image":[{"width":1400,"height":933,"url":"https:\/\/main-portal.develop-mytomorrows.com\/wp-content\/uploads\/2020\/06\/shutterstock_2292002323.jpg","type":"image\/jpeg"}],"author":"Dennis Akkaya","twitter_card":"summary_large_image","twitter_misc":{"\u0643\u064f\u062a\u0628 \u0628\u0648\u0627\u0633\u0637\u0629":"Dennis Akkaya","\u0648\u0642\u062a \u0627\u0644\u0642\u0631\u0627\u0621\u0629 \u0627\u0644\u0645\u064f\u0642\u062f\u0651\u0631":"8 \u062f\u0642\u0627\u0626\u0642"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/","url":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/","name":"A Brief History of Expanded Access (Pt. 2) 2014 - 2020 - myTomorrows","isPartOf":{"@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#website"},"primaryImageOfPage":{"@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#primaryimage"},"image":{"@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#primaryimage"},"thumbnailUrl":"https:\/\/main-portal.develop-mytomorrows.com\/wp-content\/uploads\/2020\/06\/shutterstock_2292002323.jpg","datePublished":"2020-06-10T14:21:17+00:00","dateModified":"2024-02-27T13:26:53+00:00","author":{"@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#\/schema\/person\/b7be59ac2b5f8aea751c2b85d116402e"},"breadcrumb":{"@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#breadcrumb"},"inLanguage":"ar","potentialAction":[{"@type":"ReadAction","target":["https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/"]}]},{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#primaryimage","url":"https:\/\/main-portal.develop-mytomorrows.com\/wp-content\/uploads\/2020\/06\/shutterstock_2292002323.jpg","contentUrl":"https:\/\/main-portal.develop-mytomorrows.com\/wp-content\/uploads\/2020\/06\/shutterstock_2292002323.jpg","width":1400,"height":933,"caption":"Strasbourg, France - Apr 23, 2017: Fantastic view of European Parliament headquarters view from the Freedom bridge with reflection in Ill river and all Eu Members flags waving"},{"@type":"BreadcrumbList","@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/healthcare-professionals\/a-brief-history-of-expanded-access-part-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/home\/"},{"@type":"ListItem","position":2,"name":"A Brief History of Expanded Access (Pt. 2) 2014 – 2020"}]},{"@type":"WebSite","@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#website","url":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/","name":"myTomorrows","description":"Helping patients discover and access treatments","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ar"},{"@type":"Person","@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#\/schema\/person\/b7be59ac2b5f8aea751c2b85d116402e","name":"Dennis Akkaya","image":{"@type":"ImageObject","inLanguage":"ar","@id":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/08df14c0e203d864844886d2fccb5743e4e7f8312cea375e51edd4ea0803ed6f?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/08df14c0e203d864844886d2fccb5743e4e7f8312cea375e51edd4ea0803ed6f?s=96&d=blank&r=g","caption":"Dennis Akkaya"},"description":"Based in New York and operating from the US office, Dennis holds an MSc in Finance, has over 20 years of BioPharma industry experience, and is a recognized thought leader in pre-approval access and with specific expertise in clinical trials. Over 8 years at myTomorrows, his role is pivotal in creating biopharma sponsorships. His extensive background, encompassing both BioPharma and finance, well positions him to develop strategic partnerships and drive the discussion within the pre-approval access space.","url":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/blog\/author\/dennis-akkaya\/"}]}},"_links":{"self":[{"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/posts\/3636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/comments?post=3636"}],"version-history":[{"count":3,"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/posts\/3636\/revisions"}],"predecessor-version":[{"id":4836,"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/posts\/3636\/revisions\/4836"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/media\/4839"}],"wp:attachment":[{"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/media?parent=3636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/categories?post=3636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/main-portal.develop-mytomorrows.com\/ar\/wp-json\/wp\/v2\/tags?post=3636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}